{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:55:10Z","timestamp":1781880910223,"version":"3.54.5"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40266-026-01300-1","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:04:24Z","timestamp":1777842264000},"page":"485-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Mirabegron in Frail Older Adults with Overactive Bladder"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9242-514X","authenticated-orcid":false,"given":"Christina","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"1300_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"PH Abrams","year":"2002","unstructured":"Abrams PH, Fall M, Cardozo L, et al. The standardization of terminology of lower urinary tract function: Report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167\u201378.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1300_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/nau.23897","volume":"38","author":"C D'Ancona","year":"2019","unstructured":"D\u2019Ancona C, Haylen B, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38(2):433\u201377.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"1300_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306\u201314.","journal-title":"Eur Urol"},{"issue":"6","key":"1300_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"3","key":"1300_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1464-410X.2005.05279.x","volume":"95","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Wein AJ. The urgency of the problem and the problem of urgency in the overactive bladder. BJU Int. 2005;95(3):274\u20135.","journal-title":"BJU Int"},{"key":"1300_CR6","doi-asserted-by":"crossref","unstructured":"Zhang L, Cai N, Mo L, Tian X, Liu H, Yu B. Global prevalence of overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2025;36(8):1547\u201366.\u00a0","DOI":"10.1007\/s00192-024-06029-2"},{"issue":"12","key":"1300_CR7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/03007995.2016.1226167","volume":"32","author":"ML Ganz","year":"2016","unstructured":"Ganz ML, Liu J, Zou KH, Bhagnani T, Luo X. Real-world characteristics of elderly patients with overactive bladder in the United States. Curr Med Res Opin. 2016;32(12):1997\u20132005.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"1300_CR8","doi-asserted-by":"publisher","first-page":"533","DOI":"10.4140\/TCP.n.2015.533","volume":"30","author":"BJ Zarowitz","year":"2015","unstructured":"Zarowitz BJ, Allen C, O\u2019Shea T, Tangalos E, Berner T, Ouslander JG. Clinical burden and nonpharmacologic management of nursing facility residents with overactive bladder and\/or urinary incontinence. Consult Pharm. 2015;30(9):533\u201342.","journal-title":"Consult Pharm"},{"issue":"6","key":"1300_CR9","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ageing\/afz094","volume":"48","author":"E Keeble","year":"2019","unstructured":"Keeble E, Parker SG, Arora S, Neuburger J, Duncan R, Kingston A, et al. Frailty, hospital use and mortality in the older population: findings from the Newcastle 85+ study. Age Ageing. 2019;48(6):797\u2013802.","journal-title":"Age Ageing"},{"issue":"5","key":"1300_CR10","doi-asserted-by":"publisher","first-page":"M283","DOI":"10.1093\/gerona\/57.5.M283","volume":"57","author":"WM Bortz 2nd","year":"2002","unstructured":"Bortz WM 2nd. A conceptual framework of frailty: a review. J Gerontol A Biol Sci Med Sci. 2002;57(5):M283\u20138.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"2","key":"1300_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.outlook.2009.09.005","volume":"58","author":"RJ Gobbens","year":"2010","unstructured":"Gobbens RJ, Luijkx KG, Wijnen-Sponselee MT, Schols JM. Toward a conceptual definition of frail community dwelling older people. Nurs Outlook. 2010;58(2):76\u201386.","journal-title":"Nurs Outlook"},{"issue":"1","key":"1300_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12603-013-0437-5","volume":"18","author":"JF Dartigues","year":"2014","unstructured":"Dartigues JF, Amieva H. Cognitive frailty: rational and definition from an (I.a.N.a.\/i.a.g.g.) international consensus group. J Nutr Health Aging. 2014;18(1):95.","journal-title":"J Nutr Health Aging"},{"issue":"3","key":"1300_CR13","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146\u201356.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1100\/tsw.2001.58","volume":"1","author":"AB Mitnitski","year":"2001","unstructured":"Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;1:323\u201336.","journal-title":"ScientificWorldJournal"},{"key":"1300_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2025.105068","volume":"167","author":"LN Kong","year":"2025","unstructured":"Kong LN, Yang L, Lyu Q, Liu DX, Yang J. Risk prediction models for frailty in older adults: a systematic review and critical appraisal. Int J Nurs Stud. 2025;167:105068.","journal-title":"Int J Nurs Stud"},{"key":"1300_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s42490-019-0007-y","volume":"1","author":"YN Panhwar","year":"2019","unstructured":"Panhwar YN, Naghdy F, Naghdy G, Stirling D, Potter J. Assessment of frailty: a survey of quantitative and clinical methods. BMC Biomed Eng. 2019;1:7.","journal-title":"BMC Biomed Eng"},{"key":"1300_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.arr.2015.12.003","volume":"26","author":"BJ Buta","year":"2016","unstructured":"Buta BJ, Walston JD, Godino JG, Park M, Kalyani RR, Xue QL, et al. Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev. 2016;26:53\u201361.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"1300_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018195","volume":"8","author":"DD Siriwardhana","year":"2018","unstructured":"Siriwardhana DD, Hardoon S, Rait G, Weerasinghe MC, Walters KR. Prevalence of frailty and prefrailty among community-dwelling older adults in low-income and middle-income countries: a systematic review and meta-analysis. BMJ Open. 2018;8(3):e018195.","journal-title":"BMJ Open"},{"issue":"1","key":"1300_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ageing\/afaa219","volume":"50","author":"R O'Caoimh","year":"2021","unstructured":"O\u2019Caoimh R, Sezgin D, O\u2019Donovan MR, Molloy DW, Clegg A, Rockwood K, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. 2021;50(1):96\u2013104.","journal-title":"Age Ageing"},{"issue":"8","key":"1300_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8398","volume":"2","author":"R Ofori-Asenso","year":"2019","unstructured":"Ofori-Asenso R, Chin KL, Mazidi M, Zomer E, Ilomaki J, Zullo AR, et al. Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(8):e198398.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1300_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-015-0068-x","volume":"73","author":"F Buckinx","year":"2015","unstructured":"Buckinx F, Rolland Y, Reginster JY, Ricour C, Petermans J, Bruyere O. Burden of frailty in the elderly population: perspectives for a public health challenge. Arch Public Health. 2015;73(1):19.","journal-title":"Arch Public Health"},{"issue":"5","key":"1300_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/ageing\/26.5.367","volume":"26","author":"DH Thom","year":"1997","unstructured":"Thom DH, Haan MN, Van Den Eeden SK. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality. Age Ageing. 1997;26(5):367\u201374.","journal-title":"Age Ageing"},{"key":"1300_CR23","doi-asserted-by":"crossref","unstructured":"Wang CJ, Hung CH, Tang TC, Chen LY, Peng LN, Hsiao FY, et al. Urinary Incontinence and its Association with Frailty among Men Aged 80 Years and Older in Taiwan: a Cross-Sectional Study. Rejuvenation Res. 2016.","DOI":"10.1089\/rej.2016.1855"},{"issue":"1","key":"1300_CR24","doi-asserted-by":"publisher","first-page":"M19","DOI":"10.1093\/gerona\/56.1.M19","volume":"56","author":"TP Miles","year":"2001","unstructured":"Miles TP, Palmer RF, Espino DV, Mouton CP, Lichtenstein MJ, Markides KS. New-onset incontinence and markers of frailty: data from the Hispanic Established Populations for Epidemiologic Studies of the Elderly. J Gerontol A Biol Sci Med Sci. 2001;56(1):M19-24.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"3","key":"1300_CR25","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1590\/S0080-62342011000300018","volume":"45","author":"VA Silva","year":"2011","unstructured":"Silva VA, Souza KL, D\u2019Elboux MJ. [Urinary incontinence and the criteria of frailness among the elderly outpatients]. Rev Esc Enferm USP. 2011;45(3):672\u20138.","journal-title":"Rev Esc Enferm USP"},{"issue":"11","key":"1300_CR26","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.1111\/jan.16172","volume":"80","author":"CY Wang","year":"2024","unstructured":"Wang CY, Peng SJ, Zhao M, Wu C, Wang KF. A study to untangle the puzzle of urinary incontinence and frailty co-occurrence among older adults: the roles of depression and activity engagement. J Adv Nurs. 2024;80(11):4584\u201392.","journal-title":"J Adv Nurs"},{"issue":"6","key":"1300_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00192-014-2596-2","volume":"26","author":"EA Erekson","year":"2015","unstructured":"Erekson EA, Fried TR, Martin DK, Rutherford TJ, Strohbehn K, Bynum JP. Frailty, cognitive impairment, and functional disability in older women with female pelvic floor dysfunction. Int Urogynecol J. 2015;26(6):823\u201330.","journal-title":"Int Urogynecol J"},{"issue":"3","key":"1300_CR28","first-page":"591","volume":"203","author":"R Matta","year":"2020","unstructured":"Matta R, Hird AE, Saskin R, Radomski SB, Carr L, Kodama RT, et al. Is There an Association between Urinary Incontinence and Mortality? A Retrospective Cohort Study J Urol. 2020;203(3):591\u20137.","journal-title":"A Retrospective Cohort Study. J Urol."},{"issue":"6","key":"1300_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/ggi.12543","volume":"16","author":"S Satake","year":"2016","unstructured":"Satake S, Senda K, Hong YJ, Miura H, Endo H, Sakurai T, et al. Validity of the Kihon Checklist for assessing frailty status. Geriatr Gerontol Int. 2016;16(6):709\u201315.","journal-title":"Geriatr Gerontol Int"},{"issue":"8","key":"1300_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ggi.14633","volume":"23","author":"N Irie","year":"2023","unstructured":"Irie N, Muramoto N, Shirakawa T, China T, Kawano H, Isotani S, et al. High prevalence of frailty in patients with lower urinary tract symptoms. Geriatr Gerontol Int. 2023;23(8):609\u201315.","journal-title":"Geriatr Gerontol Int"},{"key":"1300_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsialdo","year":"1991","unstructured":"Podsialdo D, Richardson S. The timed up and go\": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39:142\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"1300_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.urology.2017.03.058","volume":"106","author":"AM Suskind","year":"2017","unstructured":"Suskind AM, Quanstrom K, Zhao S, Bridge M, Walter LC, Neuhaus J, et al. Overactive bladder is strongly associated with frailty in older individuals. Urology. 2017;106:26\u201331.","journal-title":"Urology"},{"issue":"5","key":"1300_CR33","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/nau.24414","volume":"39","author":"S Song","year":"2020","unstructured":"Song S, Jin C, Kamal P, Suskind AM. The association between frailty and detrusor overactivity in older adults. Neurourol Urodyn. 2020;39(5):1584\u201391.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"1300_CR34","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/ageing\/afl041","volume":"35","author":"DB Rolfson","year":"2006","unstructured":"Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability of the Edmonton Frail Scale. Age Ageing. 2006;35(5):526\u20139.","journal-title":"Age Ageing"},{"issue":"2","key":"1300_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/luts.12292","volume":"12","author":"O Soma","year":"2020","unstructured":"Soma O, Hatakeyama S, Imai A, Matsumoto T, Hamano I, Fujita N, et al. Relationship between frailty and lower urinary tract symptoms among community-dwelling adults. Low Urin Tract Symptoms. 2020;12(2):128\u201336.","journal-title":"Low Urin Tract Symptoms."},{"issue":"3","key":"1300_CR36","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2006.01.031","volume":"50","author":"A Ponholzer","year":"2006","unstructured":"Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol. 2006;50(3):581\u20136.","journal-title":"Eur Urol"},{"issue":"8","key":"1300_CR37","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/gerona\/glp037","volume":"64","author":"GA Kuchel","year":"2009","unstructured":"Kuchel GA, Moscufo N, Guttmann CR, Zeevi N, Wakefield D, Schmidt J, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci. 2009;64(8):902\u20139.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1300_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/nau.24549","volume":"40","author":"W Gibson","year":"2021","unstructured":"Gibson W, Johnson T, Kirschner-Hermanns R, Kuchel G, Markland A, Orme S, et al. Incontinence in frail elderly persons: Report of the 6th International Consultation on Incontinence. Neurourol Urodyn. 2021;40:38\u201354.","journal-title":"Neurourol Urodyn"},{"issue":"13","key":"1300_CR39","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1111\/j.1471-0528.2011.03100.x","volume":"118","author":"A Wagg","year":"2011","unstructured":"Wagg A, Duckett J, McClurg D, Harari D, Lowe D. To what extent are national guidelines for the management of urinary incontinence in women adhered? Data from a national audit. BJOG\u202f: an international journal of obstetrics and gynaecology. 2011;118(13):1592\u2013600.","journal-title":"BJOG : an international journal of obstetrics and gynaecology"},{"key":"1300_CR40","doi-asserted-by":"crossref","unstructured":"Gibson W, Harari D, Husk J, Lowe D, Wagg A. A national benchmark for the initial assessment of men with LUTS: data from the 2010 Royal College of Physicians National Audit of Continence Care. World J Urol. 2016;34(7):969\u201377.","DOI":"10.1007\/s00345-015-1702-5"},{"issue":"1","key":"1300_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/nau.24549","volume":"40","author":"W Gibson","year":"2021","unstructured":"Gibson W, Johnson T, Kirschner-Hermanns R, Kuchel G, Markland A, Orme S, et al. Incontinence in frail elderly persons: Report of the 6th International Consultation on Incontinence. Neurourol Urodyn. 2021;40(1):38\u201354.","journal-title":"Neurourol Urodyn"},{"key":"1300_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.euros.2025.07.015","volume":"79","author":"J Oliveira","year":"2025","unstructured":"Oliveira J, Oliveira S, Vale L, Guillot-Tantay C, Cancrini F, Przydacz M, et al. Does anticholinergic burden influence therapeutic success in patients with treatment-na\u00efve overactive bladder? European Urology Open Science. 2025;79:87\u201392.","journal-title":"European Urology Open Science"},{"issue":"14","key":"1300_CR43","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1111\/bph.14658","volume":"176","author":"Y Igawa","year":"2019","unstructured":"Igawa Y, Aizawa N, Michel MC. Beta(3)-adrenoceptors in the normal and diseased urinary bladder-what are the open questions? Br J Pharmacol. 2019;176(14):2525\u201338.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1300_CR44","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","volume":"34","author":"W Krauwinkel","year":"2012","unstructured":"Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, et al. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012;34(10):2144\u201360.","journal-title":"Clin Ther"},{"issue":"4","key":"1300_CR45","doi-asserted-by":"publisher","first-page":"F859","DOI":"10.1152\/ajprenal.00215.2017","volume":"313","author":"K Okeke","year":"2017","unstructured":"Okeke K, Gravas S, Michel MC. Do beta(3)-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release? Am J Physiol Renal Physiol. 2017;313(4):F859\u201361.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"1300_CR46","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00210-015-1122-5","volume":"388","author":"J Eastham","year":"2015","unstructured":"Eastham J, Stephenson C, Korstanje K, Gillespie JI. The expression of beta3-adrenoceptor and muscarinic type 3 receptor immuno-reactivity in the major pelvic ganglion of the rat. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(7):695\u2013708.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"1300_CR47","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/nau.25483","volume":"43","author":"M Artykov","year":"2024","unstructured":"Artykov M, Ozcelebi E, Sara MY, Gudeloglu A, Iskit AB, Aki FT. In vitro effects of \u03b23-adrenoceptor agonist mirabegron on the human ureter. Neurourol Urodyn. 2024;43(7):1709\u201317.","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"1300_CR48","doi-asserted-by":"publisher","first-page":"838","DOI":"10.5414\/CP201782","volume":"50","author":"C Eltink","year":"2012","unstructured":"Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, et al. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a beta(3)-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50(11):838\u201350.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"1300_CR49","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/clpt.2012.181","volume":"92","author":"M Malik","year":"2012","unstructured":"Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696\u2013706.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1300_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40261-012-0031-3","volume":"33","author":"J Dickinson","year":"2013","unstructured":"Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig. 2013;33(1):11\u201323.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"1300_CR51","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.111.043588","volume":"40","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815\u201324.","journal-title":"Drug Metab Dispos"},{"key":"1300_CR52","first-page":"S88","volume":"85","author":"EM van Gelderen","year":"2009","unstructured":"van Gelderen EM, Li Q, Meijer JA. An exploratory comparison of the single dose pharmacokinetics of the beta 3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther. 2009;85:S88.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1300_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","volume":"42","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012;42(12):1187\u201396.","journal-title":"Xenobiotica"},{"key":"1300_CR54","unstructured":"Krauwinkel W, van Gelderen E, Groen M, Schaddelee M, de Koning P, editors. An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the cyp2d6 substrate desipramine in healthy subjects. Clinical pharmacology & therapeutics; 2010: nature publishing group 75 Varick St, 9th Flr, New York, NY 10013-1917 USA."},{"key":"1300_CR55","first-page":"85","volume":"87","author":"WJ Krauwinkel","year":"2010","unstructured":"Krauwinkel WJ, Gelderen M, Groen MJ, Schaddelee M, de Koning P. An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects. Clin Pharmacol Ther. 2010;87:85.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1300_CR56","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","volume":"82","author":"S Herschorn","year":"2013","unstructured":"Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313\u201320.","journal-title":"Urology"},{"issue":"2","key":"1300_CR57","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283\u201395.","journal-title":"Eur Urol"},{"issue":"4","key":"1300_CR58","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388\u201395.","journal-title":"J Urol"},{"issue":"2","key":"1300_CR59","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","volume":"63","author":"CR Chapple","year":"2013","unstructured":"Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296\u2013305.","journal-title":"Eur Urol"},{"issue":"5","key":"1300_CR60","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/ageing\/afu017","volume":"43","author":"A Wagg","year":"2014","unstructured":"Wagg A, Cardozo L, Nitti VW, Castro-Diaz D, Auerbach S, Blauwet MB, et al. The efficacy and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing. 2014;43(5):666\u201375.","journal-title":"Age Ageing"},{"issue":"1","key":"1300_CR61","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/luts.12190","volume":"11","author":"M Yoshida","year":"2019","unstructured":"Yoshida M, Nozawa Y, Kato D, Tabuchi H, Kuroishi K. Safety and effectiveness of mirabegron in patients with overactive bladder aged >\/=75 years: analysis of a Japanese post-marketing study. Low Urin Tract Symptoms. 2019;11(1):30\u20138.","journal-title":"Low Urin Tract Symptoms"},{"issue":"2","key":"1300_CR62","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","volume":"77","author":"A Wagg","year":"2020","unstructured":"Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged >\/=65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211\u201320.","journal-title":"Eur Urol"},{"issue":"1","key":"1300_CR63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/nau.22505","volume":"33","author":"CR Chapple","year":"2014","unstructured":"Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17\u201330.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"1300_CR64","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","volume":"32","author":"CR Chapple","year":"2014","unstructured":"Chapple CR, Nitti VW, Khullar V, Wyndaele JJ, Herschorn S, van Kerrebroeck P, et al. Onset of action of the \u03b23-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;32(6):1565\u201372.","journal-title":"World J Urol"},{"issue":"4","key":"1300_CR65","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0031-6997(24)01425-X","volume":"51","author":"OE Brodde","year":"1999","unstructured":"Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51(4):651\u201390.","journal-title":"Pharmacol Rev"},{"issue":"9","key":"1300_CR66","first-page":"3219","volume":"118","author":"VA Skeberdis","year":"2008","unstructured":"Skeberdis VA, Gendviliene V, Zablockaite D, Treinys R, Macianskiene R, Bogdelis A, et al. Beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest. 2008;118(9):3219\u201327.","journal-title":"J Clin Invest"},{"issue":"1","key":"1300_CR67","doi-asserted-by":"publisher","first-page":"e739","DOI":"10.1016\/S1569-9056(13)61221-X","volume":"12","author":"S Herschorn","year":"2013","unstructured":"Herschorn S, Kowey P, Nitti V, Milsom I, Auerbach S, Blauwet MB, et al. Cardiovascular assessments in short- and long-term Phase 3 mirabegron trials in patients with OAB. Eur Urol Suppl. 2013;12(1):e739\u201340.","journal-title":"Eur Urol Suppl"},{"issue":"1","key":"1300_CR68","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","volume":"77","author":"CR Chapple","year":"2020","unstructured":"Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, et al. Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur Urol. 2020;77(1):119\u201328.","journal-title":"Eur Urol"},{"issue":"2","key":"1300_CR69","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2015.09.007","volume":"69","author":"GM Rosa","year":"2016","unstructured":"Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular safety of beta3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311\u201323.","journal-title":"Eur Urol"},{"issue":"2","key":"1300_CR70","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1756287209103937","volume":"1","author":"KE Andersson","year":"2009","unstructured":"Andersson KE. Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol. 2009;1(2):71\u201383.","journal-title":"Ther Adv Urol"},{"issue":"1","key":"1300_CR71","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1124\/jpet.108.138651","volume":"326","author":"LA Leon","year":"2008","unstructured":"Leon LA, Hoffman BE, Gardner SD, Laping NJ, Evans C, Lashinger ES, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2008;326(1):178\u201385.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1300_CR72","first-page":"713","volume":"13","author":"P Tyagi","year":"2010","unstructured":"Tyagi P, Tyagi V. Mirabegron, a \u03b23-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs. 2010;13(10):713\u201322.","journal-title":"IDrugs"},{"issue":"4","key":"1300_CR73","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","volume":"190","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the \u03b23-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320\u20137.","journal-title":"J Urol"},{"issue":"5","key":"1300_CR74","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/01443610500160675","volume":"25","author":"OS Eskandar","year":"2005","unstructured":"Eskandar OS, Eckford SD, Whittaker KW. Treatment of overactive bladder (OBA) with anti-cholinergic drugs and the risk of glaucoma. J Obstet Gynaecol. 2005;25(5):419\u201321.","journal-title":"J Obstet Gynaecol"},{"issue":"7","key":"1300_CR75","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1442-2042.2007.01791.x","volume":"14","author":"K Kato","year":"2007","unstructured":"Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol. 2007;14(7):595\u20137.","journal-title":"Int J Urol"},{"issue":"7","key":"1300_CR76","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1089\/jop.2012.0254","volume":"29","author":"GD Novack","year":"2013","unstructured":"Novack GD, Lewis RA, Vogel R, Sheth N, Swearingen D, Rasmussen S, et al. Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther. 2013;29(7):674\u201380.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"1300_CR77","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1046\/j.1532-5415.2001.49281.x","volume":"49","author":"D Saliba","year":"2001","unstructured":"Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49(12):1691\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1300_CR78","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12894-022-00989-7","volume":"22","author":"H Nakagomi","year":"2022","unstructured":"Nakagomi H, Mitsui T, Shimura H, Ihara T, Kira S, Sawada N, et al. Mirabegron for overactive bladder in frail patients 80\u00a0years or over (HOKUTO study). BMC Urol. 2022;22(1):40.","journal-title":"BMC Urol"},{"key":"1300_CR79","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.urology.2024.07.006","volume":"191","author":"EA Enemchukwu","year":"2024","unstructured":"Enemchukwu EA, Sinclair S, Mohamud H, Zhang CA, Anger JT, Scales CD Jr. Frailty, specialized care, and sociodemographic factors: disparities in oral pharmacotherapy class utilization among Medicare Part D beneficiaries with overactive bladder in the United States. Urology. 2024;191:49\u201356.","journal-title":"Urology"},{"issue":"8","key":"1300_CR80","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/nau.25040","volume":"41","author":"TM Johnson 2nd","year":"2022","unstructured":"Johnson TM 2nd, Walker D, Lockefeer A, Jiang B, Nimke D, Lozano-Ortega G, et al. Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population. Neurourol Urodyn. 2022;41(8):1872\u201389.","journal-title":"Neurourol Urodyn"},{"issue":"11","key":"1300_CR81","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1007\/s12325-019-01098-y","volume":"36","author":"M Ali","year":"2019","unstructured":"Ali M, Grogan S, Powell S, Staniford L, Nazir J, Landeira M, et al. Qualitative analysis of factors influencing patient persistence and adherence to prescribed overactive bladder medication in UK primary care. Adv Ther. 2019;36(11):3110\u201322.","journal-title":"Adv Ther"},{"key":"1300_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph17010116","volume":"17","author":"M Malkowski","year":"2024","unstructured":"Malkowski M, Almgren-Rachtan A, Olszanecka-Glinianowicz M, Chudek J, Chlosta P. Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists. Pharmaceuticals (Basel). 2024;17:1.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"1300_CR83","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","volume":"41","author":"P Fardellone","year":"2019","unstructured":"Fardellone P, Lello S, Cano A, de S\u00e1 Moreira E, Watanabe de Oliveira R, Julian GS, et al. Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: A systematic review. Clin Ther. 2019;41(8):1576\u201388.","journal-title":"Clin Ther"},{"issue":"11","key":"1300_CR84","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1001\/jamapsychiatry.2017.3047","volume":"74","author":"JA Sirey","year":"2017","unstructured":"Sirey JA, Banerjee S, Marino P, Bruce ML, Halkett A, Turnwald M, et al. Adherence to Depression Treatment in Primary Care: A Randomized Clinical Trial. JAMA Psychiat. 2017;74(11):1129\u201335.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"1300_CR85","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1097\/JU.0000000000001440","volume":"205","author":"YS Song","year":"2021","unstructured":"Song YS, Lee HY, Park JJ, Kim JH. Persistence and adherence of anticholinergics and Beta-3 agonist for the treatment of overactive bladder: systematic review and meta-analysis, and network meta-analysis. J Urol. 2021;205(6):1595\u2013604.","journal-title":"J Urol"},{"issue":"11","key":"1300_CR86","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021889","volume":"8","author":"G Yeowell","year":"2018","unstructured":"Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and Mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889.","journal-title":"BMJ Open"},{"key":"1300_CR87","doi-asserted-by":"crossref","unstructured":"Sussman D, Yehoshua A, Kowalski J, Lee W, Kish J, Chaudhari S, et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: A real-world claims data analysis. Int J Clin Pract. 2017;71(3\u20134):e12824.","DOI":"10.1111\/ijcp.12824"},{"key":"1300_CR88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ijcp.12996","volume":"71","author":"AS Wagg","year":"2017","unstructured":"Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database. Int J Clin Pract. 2017;71:10.","journal-title":"Int J Clin Pract"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01300-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:02:54Z","timestamp":1780506174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01300-1","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CS has no competing interests. AW reports the receipt of speaker honoraria from Astellas Pharma and Becton-Dickinson, consultancy from Becton-Dickinson and support for research from Essity Healthcare and Hygiene AB and Becton-Dickinson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation & publication)"}},{"value":"All authors contributed to the final version of the article. The first draft of the manuscript was written by CS; additional writing and edits were completed by AW; and revisions were completed by CS. All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}